ubiquitin specific peptidase 17 like family member 14, pseudogeneGenealiases: []
Q-omics provides the consensus-scored USP17L14P profile across patient tissues and cancer cell-line models. USP17L14P expression is associated with patient survival in 3 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, USP17L14P is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, USP17L14P RNA expression shows 3,027 significant gene co-expression associations, with the highest sampling consensus in BRCA. Together, these results highlight MESO, and BRCA as cancer lineages where USP17L14P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP17L14P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes USP17L14P survival associations across molecular data types. USP17L14P RNA expression shows survival associations in the most cancer types (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP17L14P RNA expression–survival associations across cancer types. High USP17L14P expression shows unfavorable associations in MESO, LUSC and ACC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for USP17L14P RNA expression.
This table summarizes USP17L14P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for USP17L14P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. USP17L14P shows higher tumor expression in BRCA. The BRCA box plot shows higher USP17L14P RNA expression in tumor versus normal tissue (log2 FC = +0.003, t-test p = .029).
This table shows molecular features associated with USP17L14P in patient tissues and cancer cell lines. In patient samples, USP17L14P shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
